Some of the patients who Beth Unger has investigated do not have PEM. I forget the percentage, but I think she said that roughly 87% of a cohort that she has investigated had PEM. (I'm not certain what patients she was referring to - perhaps she was referring to those from the expert clinics in her multi-site trial - but it might have been another cohort.) She has a duty to serve those patients without PEM, as well as those with PEM, whatever we think about it.
Just as a point of discussion, perhaps it might be helpful for our community to subtly change our approach to our advocacy, in order to achieve the best outcome with the CDC in the short term. At the moment, many of us tend to say that ME has PEM, end of story. But that's not the end of the story for Beth Unger, because some of her patient cohort does not have PEM.
So perhaps we need to encourage her to subgroup CFS patients, into those with and without PEM, rather than simply disregarding those without PEM? Her response, in the letter above, suggests that's the direction she's travelling, and if that's what she's doing anyway, then perhaps we should encourage her, as a step in the right direction? It would be a step forwards if PEM was recognised by the CDC to be a factor in a large subset of CFS patients (we might describe these patients as having ME rather than CFS, but Beth Unger might prefer to describe them as being a subset of CFS patients.)
If we could reach a compromise like that, then the next step would be to get the PEM patients treated and investigated as a separate cohort. One step at a time. It would be a massive step in the right direction to have PEM recognised as a prerequisite for a subset of CFS patients. Perhaps we could think about encouraging the CDC to use labelling such as "CFS typical" (for patients with PEM") and "CFS atypical" (for patients without PEM), until the CDC is ready to use the separate labels of 'CFS' (for patients without PEM), and 'ME' (for patients with PEM).
Just some thoughts. What do you all think?